Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
Sponsor: GAIA BioMedicine Inc.
Summary
Phase I Part : Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II. Phase II Part : Explore the efficacy and safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer at the recommended dose of GAIA-102 decided in the Phase I part.
Official title: Phase I / II Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2021-12-01
Completion Date
2026-03-06
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
Biological
Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
Locations (3)
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Kitakyushu Municipal Medical Center
Kitakyushu, Fukuoka, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan